The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Research Identifies Two New Cell Types in Sjögren’s Syndrome

Research Identifies Two New Cell Types in Sjögren’s Syndrome

January 9, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Research has revealed two previously unidentified cellular players in the pathogenesis of primary Sjögren’s syndrome (pSS): a regulatory T cell (Prdm1+eTreg) and a helper T cell (Il21+Th1). Scott Haskett, MSc, a scientist at Biogen in Cambridge, Mass., and colleagues published the results of their research in NOD mice and patients with pSS online on Oct. 7 in the Journal of Immunology.1

You Might Also Like
  • Dysbiosis of Gut, But Not Ocular Microbiome, Associated with Sjögren’s Syndrome
  • Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype
  • Protein Phosphatase 2A and Regulatory T Cell Function Researched
Also by this Author
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis

“Advancing our knowledge of the pathogenic cell subsets infiltrating exocrine glands in pSS patients has been limited by the low dimensionality of traditional histology techniques and the limited number of cells available for single-cell analyses in lip biopsy samples,” write the authors in their discussion. “In this study, we took advantage of the NOD model of pSS, which displays extensive immune infiltration in LGT [lacrimal gland tissue] that is accompanied by the upregulation of 58% of the human pSS transcriptional signature. In inflamed LGT from this model, we identified a population of Tregs as the most abundant CD4+ T cell subset, accounting for up to 50% of the entire population at the peak of immune infiltration.”

The investigators began their work with an integrated analysis of publicly available mouse and human pSS datasets, from which they identified an upregulated transcriptional gene signature. “To better define the phenotype of infiltrating cells, we next isolated LGT CD4+ T cells, as well as their splenic counterparts, from 16-wk-old NOD mice,” explain the authors. “To account for any transcriptional changes caused by LGT processing that would affect all cells, irrespective of their cellular identity, we also isolated B cells from the same tissue.” They then identified the subsets of T cells that contributed to the LGT CD4+ T cell pool.

The researchers purified the LGT-infiltrating T cell subsets and performed gene-expression analyses to characterize their cellular and molecular identities. The transcriptional signatures and transcription factor profiles of the PD1high ICOShigh T cell subsets allowed the investigators to further refine the transcriptional identity of these subsets. The Il2l+ Th1 cells were defined by Pd1highICOShighCD73highCd200high phenotype and high expression of Ifng, Thx21, Tnf and IL2. These cells were not only found in the NOD mouse model of pSS, but also in salivary gland biopsies from patients with pSS. In contrast, the investigators did not find the cells in normal salivary glands or kidney biopsies from patients with lupus nephritis. The team also noted that the cells had transcriptional similarity with a different CD4+ T cell subset that had been described in lupus-prone B6.Sle1b and BWF1 mouse models. Thus, the transcriptomes from effector and regulatory subsets identified in the LGT from NOD mice were not unique to the tissue or disease model.

Pages: 1 2 Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: cells, Pathogenesis, regulatory T cell, Sjogren's syndrome, T cell

You Might Also Like:
  • Dysbiosis of Gut, But Not Ocular Microbiome, Associated with Sjögren’s Syndrome
  • Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype
  • Protein Phosphatase 2A and Regulatory T Cell Function Researched
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Meeting Abstracts

Browse and search abstracts from the ACR Annual Meetings going back to 2012.

Visit the ACR Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2018 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.